-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $205

Benzinga·05/02/2025 18:40:54
Listen to the news
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $217 to $205.